BioCentury
ARTICLE | Financial News

Synthetic biology play Senti debuts with $53M series A

February 27, 2018 12:35 PM UTC

Senti Biosciences Inc. (South San Francisco, Calif.) announced a tranched $53 million series A round led by existing investor New Enterprise Associates (NEA). 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Co., Nest.Bio, Omega Funds, Goodman Capital and LifeForce Capital also participated.

Senti co-founder and CEO Timothy Lu told BioCentury that the synthetic biology company raised about 70% of the round in the current tranche...

BCIQ Company Profiles

Senti Biosciences Inc.